Automating the Determination of Drug-to-Antibody Ratio (DAR) of Antibody Drug Conjugates (ADCs) Based on Separation by Hydrophobic Interaction Chromatography (HIC)

Importance of Topic

Antibody–drug conjugates (ADCs) are an emerging class of cancer therapeutics that combine the high specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. Monitoring the drug-to-antibody ratio (DAR) during ADC development and manufacturing is critical to ensure consistent efficacy, safety, and quality, as variations in DAR impact pharmacokinetics, potency, and stability of the final biotherapeutic product.

Objectives and Study Overview

This application note demonstrates an automated workflow for determining DAR values of cysteine-conjugated ADCs using hydrophobic interaction chromatography (HIC) coupled with Empower 3 chromatography data software. The study aims to streamline data acquisition, processing, and reporting by integrating custom calculation tools to minimize manual intervention and enhance throughput.

Methodology and Used Instrumentation

A cysteine-conjugated ADC at 2 mg/mL in 1 M ammonium sulfate was analyzed on a Protein-Pak Hi Res HIC column (4.6 × 100 mm, 2.5 µm) using an ACQUITY UPLC H-Class system with TUV detection at 280 nm. The mobile phase gradient employed high salt loading followed by decreasing ionic strength to separate DAR species (0, 2, 4, 6, and 8). Empower 3 Software managed data collection, peak grouping via timed retention windows, and custom field calculations for automated DAR computation.

Key Results and Discussion

The HIC separation yielded distinct clusters of peaks corresponding to each DAR species. Empower’s Timed Groups feature reliably grouped positional isomers within defined retention time windows. Custom fields, configured to apply formulas only to grouped peaks, calculated individual and total DAR values directly from peak areas. Across multiple batches, the automated method produced consistent DAR readouts (e.g., DAR2, DAR4, DAR6, DAR8) with minimal operator input. The integrated approach reduced analysis time and potential transcription errors associated with manual calculations.

Benefits and Practical Applications

• Increased productivity by automating DAR calculations and reporting.
• Improved data consistency through predefined grouping and formula application.
• Streamlined QC workflow with custom report templates for rapid review.
• Scalable solution adaptable to various ADC chemistries and chromatographic methods.

Future Trends and Opportunities

Ongoing developments in ADC analytics will emphasize higher-throughput separations, advanced informatics for multi-attribute monitoring, and integration with quality by design (QbD) frameworks. Machine learning models may further refine peak identification, while real-time process monitoring could move DAR determination in-line with bioreactor production. Expansion of workflow automation to other critical quality attributes will continue to streamline ADC development pipelines.

Conclusion

The presented workflow using ACQUITY UPLC H-Class chromatography and Empower 3 Software delivers a fully automated, robust method for DAR determination of cysteine-conjugated ADCs. By integrating custom fields for DAR calculation with timed peak grouping and flexible reporting, this solution enhances analytical efficiency, data reliability, and regulatory compliance in biopharmaceutical laboratories.

Reference

• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010 Aug;14(4):529–37.
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005 Sep;23(9):1137–46.
• Wakankar A, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011 Mar-Apr;3(2):161–72.